EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck
Stopped Study terminated due to potential safety concerns in combination with platinum-based therapies
Conditions
- Squamous Cell Carcinoma of the Head and Neck
Interventions
- DRUG: EMD 1201081 + 5-FU + Cisplatin + Cetuximab
- DRUG: EMD 1201081 + 5-FU + Cisplatin + Cetuximab
Sponsor
Merck KGaA, Darmstadt, Germany